Business - Briefly   

Granules India acquires stake in Chinese firm

CHENNAI: Granules India has signed a memorandum of understanding with Hubei Biocause Heilen Pharmaceutical company (Biocause) of China. Granules has acquired a 50 per cent stake in the company to manufacture and sell pharmaeutical APIs (Active Pharmaceutical Ingredients). Under the agreement, the manufacturing assets of Biocause, located in Jingmen (China) and currently manufacturing ibuprofen, will be transferred to the joint venture.

Printer friendly page  
Send this article to Friends by E-Mail

Stories in this Section

RBI for unified consumer index
GSPC invites bids from four oil majors
Mumbai Airport's big plans
Sensex stages smart rally
HMT (Int'l) pays 20 p.c. dividend
Hutch opens two more shops
Wage ceiling up for ESI coverage
Industrial environment improving, says Vayalar Ravi
Cochin airport to adopt CUTE reservation system
Priority sector lending in Malappuram up Rs. 331 crore
LMC starts India operations
Eppinger plant to go on stream
`IT, ITeS sectors leading hirers'
Claris Lifesciences' plans
Rupee posts further gains
Exchange rates
Bullion rates
LIC Mutual Fund's new plan
Generation Next launches learning system
Union Bank raises Rs. 300 cr tier -I capital
Canara Bank's central processing unit
Granules India acquires stake in Chinese firm
TNPL pays 15 p.c. interim
Aztecsoft Q2 net up
GlobeOp opens third office
Net-O2, Agilent Technologies tie-up
New ED for Bank of Baroda
New Senior VP for SlashSupport
Idea Cellular enters Rajasthan
BG to invest $30 m for city gas projects
IFC to invest $100 m in HDFC Bank bonds
IIP up 9.7 p.c. in August

Copyright © 2006, The Hindu. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu